AIM: To investigate the postoperative transfusion and complication rates of anemic and @entity2720 @entity1 given @entity927 ( @entity928 ). METHODS: A cross-sectional prospective study was conducted of primary hip and knee arthroplasty cases performed from 11/2012 to 6/2014. Exclusion criteria included revision arthroplasty, bilateral arthroplasty, acute arthroplasty after @entity174 , and contraindication to @entity928 . @entity1 were screened prior to surgery, with @entity417 was defined as hemoglobin of less than 12 g/dL for females and of less than 13 g/dL for males. @entity1 were divided into four different groups, based on the type of arthroplasty (total hip or total knee) and hemoglobin status (anemic or nonanemic). Intraoperatively, all @entity1 received 2 g of intravenous @entity928 during surgery. Postoperatively, allogeneic blood transfusion (ABT) was directed by both clinical symptoms and relative hemoglobin change. Complications were recorded within the first two weeks after surgery and included @entity1031 , @entity281 , and wound breakdown. The differences in transfusion and complication rates, as well as the relative hemoglobin change, were compared between anemic and nonanemic groups. RESULTS: A total of 232 @entity1 undergoing primary joint arthroplasty were included in the study. For the total hip arthroplasty cohort, 21% (18/84) of @entity1 presented with preoperative @entity417 . Two @entity1 in the anemic group and two @entity1 in the nonanemic group needed ABTs; this was not significantly different (P = 0.20). One @entity1 in the anemic group presented with a @entity1211 while no @entity1 in the nonanemic group had an acute complication; this was not significantly different (P = 0.21). For nonanemic @entity1 , the average change in hemoglobin was 2.73    1.17 g/dL. For anemic @entity1 , the average change in hemoglobin was 2.28    0.96 g/dL. Between the two groups, the hemoglobin difference of 0.45 g/dL was not significant (P = 0.13). For the total knee arthroplasty cohort, 18% (26/148) of @entity1 presented with preoperative @entity417 . No @entity1 in either group required a blood transfusion or had an @entity260 . For nonanemic @entity1 , the average change in hemoglobin was 1.85    0.79 g/dL. For anemic @entity1 , the average change in hemoglobin was 1.09    0.58 g/dL. Between the two groups, the hemoglobin difference of 0.76 g/dL was significant (P < 0.001). CONCLUSION: @entity928 administration results in low transfusion and complication rates and may be a useful adjunct for TJA @entity1 with preoperative @entity417 .

Can @entity927 change preoperative @entity417 management during XXXX ?

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity260 :: ('MESH:D011183', 'Disease') :: ['acute postoperative complication'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['nonanemic total joint arthroplasty'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['deep venous thromboembolism']
@entity2720 :: (MESH:D007592,Disease) :: ['total joint arthroplasty']
